Efficacy and Safety of Yangxinshi Tablets in the Treatment of Chronic Heart Failure,a Meta Analysis
Chen Qinyue
Dai Xiaohua
Abstract：Objective To evaluate the clinical efficacy and safety of Yangxinshi tablets in the adjuvant treatment of chronic heart failure (CHF).Methods We searched the databases.The retrieval time was up to November 2017,the clinical randomized controlled trials (RCTs) about the efficacy of Yangxinshi tablets plus conventional western medicine versus western medicine in the treatment of CHF were collected.Meta-analysis was performed using Reviews Manger 5.3 software for Meta analysis after data extraction independently by 2 researchers and quality evaluation by modified Jadad.Results The results of 14 studies were included,all of them in Chinese,of which Jadad score was 2 in 1 article and 1 in 13 articles.Meta analysis showed that compared with control group,Yangxinshi tablets improved the clinical efficacy[OR=3.24,95％ CI (2.33,4.49),P ＜0.000 01],improved the 6 min walking distance(6 MWT)[MD =47.21,95％ CI (37.45,56.97),P ＜ 0.000 01],reduced the levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP)[-SMD =-1.57,95％ CI (-2.50,-0.63),P =0.001],lowered the levels of high-sensitivity C-reactive protein (hs-CRP)[MD=-0.39,95％ CI (-0.80,0.02),P =0.06].There was no significant difference in the adverse reactions between two groups (P ＞0.05).Conclusion Yangxinshi tablets in the adjuvant treatment of CHF can improve cardiac function.The existing literature quality is poor,the exact conclusion still needs further rigorous trials.
Keywords：chronic heart failureYangxinshi tabletsrandomized controlled trialsmeta analysis6 min walking distancehigh-sensitivity C-reactive protein
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 129-133 )